GenSight Biologics (SIGHT) H1 2024 earnings summary

Executive summary

• Operating income fell 36.4% to €1.7m for H1 2024, driven by changes in refund liability valuation and rebate obligations after EMA application withdrawal.

• Net loss narrowed to €5.8m from €12.0m year-over-year, with loss per share at €(0.07) versus €(0.26) in H1 2023.

• Achieved a 60% reduction in cash outflow compared to the same period in 2023 through financial discipline and renegotiation of obligations.

• Two capital increases in February and May 2024 raised €14.3m gross, improving liquidity and supporting ongoing operations.

• Statutory auditors highlighted substantial doubt about going concern due to persistent uncertainties.

Financial highlights

• Operating income: €1.7m (down from €2.7m in H1 2023).

• Net loss: €5.8m (improved from €12.0m in H1 2023); EPS: €(0.07) vs. €(0.26).

• Cash and cash equivalents: €6.9m at June 30, 2024 (up from €2.1m at Dec 31, 2023).

• R&D expenses: €6.3m (down 47.6% year-over-year).

• Sales & marketing expenses: €0.3m (down 94.6% year-over-year).

Outlook and guidance

• Cash runway extends to mid-November 2024, with potential extension to Q3 2025 if AAC/CAP resumes and generates expected proceeds.

• Additional refinancing will be required by Q3 2025, or earlier if AAC/CAP proceeds are delayed.

• Ongoing search for new financing, partnerships, or M&A opportunities to support operations and Phase III trial launch.

• LUMEVOQⓇ drug product batch expected to be released for human use in mid-October 2024, with proceeds from AAC restart anticipated from November 2024.